Self-injecting GLP-1s at home: what chronic illness TikTok gets right and wrong
Quick answer
The video appears to show self-administration of a subcutaneous GLP-1 receptor agonist using an auto-injector pen, with the thigh as the injection site. The fragmented transcript makes it difficult to confirm whether full technique, including cap removal order, button hold duration, and post-injection needle safety, was executed correctly. No drug name, dose, or clinical indication is stated, which limits the ability to assess accuracy against a specific prescribing protocol.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @krissyleigh123 actually say?
The transcript here is rough. Honestly, the audio is nearly unintelligible in places, which is itself a problem when 200,000 people are watching someone demonstrate a subcutaneous injection. What we can piece together: she removes two caps from what appears to be an auto-injector pen, identifies a "sub cue needle" (subcutaneous needle), finds an injection site she calls her "file" (likely thigh), and counts while pressing the button. She mentions the injection is "finished" and signs off referencing her "pale legs."
The caption frames this as an unfiltered look at chronic illness life, positioned around the GLP-1 medication category. No drug name is stated in the transcript. No dose is mentioned. No explicit technique instruction is given in clear language. What the viewer is left with is a fragmented visual demonstration with minimal verbal guidance.
That ambiguity is the core issue here. When injection technique content reaches this scale, vague is dangerous.
Does the science back this up?
The underlying behavior, self-administering a subcutaneous GLP-1 injection using an auto-injector pen, is medically standard and well-documented. The question is whether the technique shown aligns with clinical guidelines. On that, the transcript gives us too little to be confident either way.
Auto-injector pens for GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are designed for patient self-administration. The FDA-approved prescribing information for semaglutide specifies injection into the abdomen, thigh, or upper arm, with site rotation to reduce lipohypertrophy risk. A 2020 review by Polak et al. in Diabetes Technology and Therapeutics confirmed that injection site rotation and proper subcutaneous depth are associated with better drug absorption and reduced local adverse reactions.
The thigh site she appears to use is clinically acceptable. Holding the button down for a count of several seconds, which she appears to do, is consistent with manufacturer instructions to ensure full dose delivery. These parts check out, as far as we can tell.
What did they get wrong (or right)?
Credit where it is due: using the thigh as an injection site is legitimate, and a slow button press is correct technique. The language "sub cue needle" suggests she understands this is a subcutaneous, not intramuscular, injection. That distinction matters clinically.
What is harder to defend is the lack of any clear guidance on needle disposal. Sharps safety is not optional content. The CDC estimates that 7.8 billion needles are used annually by non-professional patients in the U.S., and improper disposal is a documented public health concern. A video watched by 200,000 people showing an injection with zero mention of a sharps container is a gap, not a personal choice.
The transcript also contains what sounds like accidental pressure on the plunger before intended injection, "I want this stuff to drop everywhere," which if accurate, could represent wasted medication or a priming error. Priming a GLP-1 auto-injector incorrectly can result in dose loss. That is not a minor mistake at current medication prices.
What should you actually know?
If you are self-injecting a GLP-1 medication, the mechanics matter more than they look in a casual TikTok. First, needle cap removal order is specific to device type. Do not improvise. Always follow the instructions for your specific pen, as Ozempic, Wegovy, Mounjaro, and Zepbound pens are not identical in their cap systems.
Second, subcutaneous injection depth depends on pinching technique and body composition. A 2019 study by Kreugel et al. in Diabetes Care found that incorrect injection depth, going intramuscular instead of subcutaneous, affects insulin pharmacokinetics and likely affects GLP-1 absorption similarly.
Third, sharps disposal is a legal requirement in many U.S. states. The FDA provides a sharps disposal locator at safeneeedledisposal.org. This is not optional lifestyle content. It is a public health responsibility.
Finally, if your medication appears to have partially dispensed before injection, contact your pharmacy or prescriber. Do not attempt a partial re-dose. GLP-1 medications are dosed weekly or daily depending on the drug, and mistimed or partial doses can affect tolerability and efficacy.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Self-injecting GLP-1s at home: what chronic illness TikTok gets right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Self-injecting GLP-1s at home: what chronic illness TikTok gets right and wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The video appears to show self-administration of a subcutaneous GLP-1 receptor agonist using an auto-injector pen, with the thigh as the injection site.
FormBlends verdict
The video appears to show self-administration of a subcutaneous GLP-1 receptor agonist using an auto-injector pen, with the thigh as the injection site. The fragmented transcript makes it difficult to confirm whether full technique, including cap removal order, button hold duration, and post-injection needle safety, was executed correctly. No drug name, dose, or clinical indication is stated, which limits the ability to assess accuracy against a specific prescribing protocol.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video appears to show self-administration of a subcutaneous GLP-1 receptor agonist using an auto-injector pen, with the thigh as the injection site. The fragmented transcript makes it difficult to confirm whether full technique, including cap removal order, button hold duration, and post-injection needle safety, was executed correctly. No drug name, dose, or clinical indication is stated, which limits the ability to assess accuracy against a specific prescribing protocol.
- GLP-1 auto-injector pens for semaglutide and tirzepatide have device-specific cap removal sequences. Following manufacturer instructions exactly is not optional, as incorrect steps can result in dose loss or accidental needle exposure.
- The thigh is a clinically approved injection site for GLP-1 medications. Site rotation across abdomen, thigh, and upper arm is recommended to reduce lipohypertrophy, per FDA prescribing information for Ozempic and Wegovy.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GLP-1 auto-injector pens for semaglutide and tirzepatide have device-specific cap removal sequences. Following manufacturer instructions exactly is not optional, as incorrect steps can result in dose loss or accidental needle exposure.
- The thigh is a clinically approved injection site for GLP-1 medications. Site rotation across abdomen, thigh, and upper arm is recommended to reduce lipohypertrophy, per FDA prescribing information for Ozempic and Wegovy.
- Kreugel et al. (2019, Diabetes Care) found that incorrect injection depth, going intramuscular instead of subcutaneous, alters drug pharmacokinetics, meaning technique errors are not cosmetic, they affect how your medication works.
- Sharps disposal is legally required in many U.S. states and is not optional content to skip in an injection tutorial. The FDA sharps disposal locator is available at safeneedledisposal.org.
- If you suspect your auto-injector partially dosed before or during injection, do not attempt to re-dose. Contact your prescribing provider or pharmacist before your next scheduled dose.
- The 200,000-view scale of this content means even small technique ambiguities get replicated at significant public health scale. Injection tutorials without clear verbal instruction are a risk, regardless of the creator's intent.
- Compounded versions of semaglutide or tirzepatide may use different delivery devices than brand-name pens. Technique demonstrated for one device cannot be assumed to transfer to a compounded formulation or a different pen model.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Krissy | Leigh | Digital 🇨🇦 · TikTok creator
200.3K views on this video
Weekly ‘stab myself with a pen’ club 💉✨ Life with chronic illness means adding this to the chaos list. Not pretty, not fun, but it’s part of surviving. Sharing because someone out there needs to see the unfiltered side of this too. 🩵 #ChronicallyIll #ChronicLifeUnfiltered #LifeWithChronicIllness
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Krissy | Leigh | Digital 🇨🇦, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.